<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM 'BioC.dtd'>
<collection>
  <source>SourceData</source>
  <date>00000000</date>
  <key>sourcedata.key</key>
  <document>
    <id>4298015 Figure_1-A</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 1-A</infon>
    <infon key="sourcedata_figure_dir">Figure_1-A</infon>
    <passage>
      <offset>0</offset>
      <text>A Representative Gli1ZF/DNA structure extrapolated from MD trajectories. Gli1ZF is shown as blue cartoon, residues involved in binding to DNA (based on single point mutation study) are shown as magenta sticks, and Zn ions as gray spheres.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_1-B</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 1-B</infon>
    <infon key="sourcedata_figure_dir">Figure_1-B</infon>
    <passage>
      <offset>0</offset>
      <text>B Effect of Gli1ZF mutants on the binding affinity to DNA as predicted by in silico alanine scanning. The &#8710;&#8710;G was calculated along MD trajectories as the difference between the &#8710;G of each Gli1ZF alanine mutant and Gli1ZF&#8208;WT. Results are shown as &#8710;&#8710;G values in kcal/mol calculated by means of the MM&#8208;PBSA methods &#177; SEM.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_1-C</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 1-C</infon>
    <infon key="sourcedata_figure_dir">Figure_1-C</infon>
    <passage>
      <offset>0</offset>
      <text>C Effect of Gli1ZF mutants on Gli1&#8208;dependent transcriptional activation. Luciferase assay was performed in HEK293T cells transfected with 12XGliBS&#8208;Luc (GliBS, Gli binding site), pRL&#8208;TK Renilla (normalization control), Flag&#8208;Gli1 WT or the indicated Flag&#8208;Gli1 mutants. Data show the mean &#177; SD of three independent experiments. *P 0.01; **P 0.05 versus Gli1 WT. Western blot analysis of Flag&#8208;Gli1 WT or the indicated Flag&#8208;Gli1 mutant expression levels (bottom panel).</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_1-E</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 1-E</infon>
    <infon key="sourcedata_figure_dir">Figure_1-E</infon>
    <passage>
      <offset>0</offset>
      <text>E Gli1/DNA binding. Double&#8208;stranded oligonucleotide containing the canonical GliBS sequence (5&#8242;-TTGCCTACCTGGGTGGTCTCTCCACTT-3&#8242;) or mutated GliBS sequence used as control (5&#8242;-TTGCCTACCTCCCACTTCTCTCCACTT-3&#8242;) was used as probe (P) in EMSA experiments. The assay was performed using recombinant GST&#8208;Gli1ZF&#8208;WT (Gli1 zinc finger fragment: aa 242-424), GST&#8208;Gli1ZF&#8208;K350A and GST&#8208;Gli1ZF&#8208;K340A. The graph on the right indicates ratio (mean arbitrary units &#177; SD from three independent experiments) of GST&#8208;Gli1ZF&#8208;WT or GST&#8208;Gli1ZF mutants bound to the labeled GliBS probe/GliBS&#8208;free probe normalized to the amount of GST&#8208;Gli1ZF&#8208;WT/DNA binding (as described in ). *P 0.05 versus Gli1 WT.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_2-A</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 2-A</infon>
    <infon key="sourcedata_figure_dir">Figure_2-A</infon>
    <passage>
      <offset>0</offset>
      <text>A Inhibition of Gli1&#8208;induced transcription in transfected HEK293T cells. HEK293T cells were transfected with 12XGliBS&#8208;Luc and pRL&#8208;TK Renilla (normalization control) plus control (empty) or Gli1 vector and treated with increasing concentrations of GlaB or GANT61. Treatment time was 24 h, and control cells were treated with DMSO only.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_2-B</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 2-B</infon>
    <infon key="sourcedata_figure_dir">Figure_2-B</infon>
    <passage>
      <offset>0</offset>
      <text>B GlaB chemical structure with numbering scheme for NMR analysis.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_2-C</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 2-C</infon>
    <infon key="sourcedata_figure_dir">Figure_2-C</infon>
    <passage>
      <offset>0</offset>
      <text>C Inhibition of Gli1&#8208;induced transcription in transfected Smo&#8722;/&#8722;MEF cells. Smo&#8722;/&#8722;MEF cells were transfected with 12XGliBS&#8208;Luc and pRL&#8208;TK Renilla (normalization control) plus control (empty) or Gli1 vector and treated for 24 h with increasing concentrations of GlaB or DMSO only as control.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_2-D</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 2-D</infon>
    <infon key="sourcedata_figure_dir">Figure_2-D</infon>
    <passage>
      <offset>0</offset>
      <text>D The graphs show the Hh target gene expression levels in Ptch1&#8722;/&#8722;MEFs treated for 48 h with GlaB and DMSO as a control. mRNA levels were determined by quantitative real&#8208;time PCR (qRT-PCR) normalized to endogenous control (&#946;2&#8208;microglobulin and HPRT). Pfkfb3 gene was used as a negative control.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_2-F</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 2-F</infon>
    <infon key="sourcedata_figure_dir">Figure_2-F</infon>
    <passage>
      <offset>0</offset>
      <text>F SuFu&#8722;/&#8722;MEFs were treated for 48 h with GlaB and DMSO as a control. Gli1 and Ptch1mRNA levels were determined by qRT-PCR normalized to &#946;2&#8208;microglobulin and HPRT expression. Pfkfb3 gene was used as a negative control.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_2-G</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 2-G</infon>
    <infon key="sourcedata_figure_dir">Figure_2-G</infon>
    <passage>
      <offset>0</offset>
      <text>G Promoter occupancy of Gli1 is prevented by GlaB treatment. MEF WT cells were transfected with Flag&#8208;tagged Gli1 or empty vectors, and chromatin immunoprecipitation (ChIP) was carried out. qRT-PCR was performed using primers encompassing the Gli&#8208;BS of mouse Ptch1 promoter (right, schematic representation). Results are indicated as fold difference, relative to empty (pcDNA3) control.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_2-H</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 2-H</infon>
    <infon key="sourcedata_figure_dir">Figure_2-H</infon>
    <passage>
      <offset>0</offset>
      <text>H Ptch1 mRNA expression levels (left panel) were determined by qRT-PCR in Daoy cells transfected with siRNA specific for Gli1 and Gli2 (siGli1/2) or a non&#8208;specific control siRNA (siCtr) and treated for 24 h with GlaB or DMSO as a control. (right panel) The graph shows Gli1 and Gli2mRNA expression levels determined by qRT-PCR in Daoy cells transfected with siGli1/2 or siCtr. Results are expressed as fold repression relative to control, and data were normalized to GAPDH and HPRT expression.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_3-A</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 3-A</infon>
    <infon key="sourcedata_figure_dir">Figure_3-A</infon>
    <passage>
      <offset>0</offset>
      <text>A The predicted binding mode of GlaB (green sticks) to Gli1ZF (blue cartoons). Residues highlighted by the single&#8208;point mutation study to impact on Gli1 binding to DNA are shown as blue sticks; K340 and K350 of the GlaB binding site are colored magenta. GlaB protons highlighted by the NMR study are shown as orange spheres.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_3-B</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 3-B</infon>
    <infon key="sourcedata_figure_dir">Figure_3-B</infon>
    <passage>
      <offset>0</offset>
      <text>B Detail of GlaB binding to Gli1ZF&#8208;WT, Gli1ZF&#8208;K340A, GLI1ZF&#8208;K350A, GLI1ZF&#8208;K340A/K350A mutants and respective theoretical affinity values. Gli1 is shown as blue transparent surface; K340 and K350 are colored magenta. GlaB is shown as green sticks.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_3-C</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 3-C</infon>
    <infon key="sourcedata_figure_dir">Figure_3-C</infon>
    <passage>
      <offset>0</offset>
      <text>C Inhibition of Gli1/DNA binding by GlaB. EMSA using recombinant GST&#8208;Gli1ZF&#8208;WT or GST&#8208;Gli1ZF&#8208;K340A in the presence of different concentrations of GlaB or with DMSO only. The shifted complex is competed with a 50&#215; excess of cold probe. The graph on the right indicates ratio (mean arbitrary units &#177; SD from three independent experiments) of GST&#8208;Gli1ZF&#8208;WT or GST&#8208;Gli1ZF&#8208;K340A bound to the labeled GliBS probe/GliBS&#8208;free probe normalized to the amount of GST&#8208;Gli1ZF&#8208;WT/DNA binding in absence of GlaB. *P  0.05 versus DMSO; **P  0.05 K340A + GlaB versus Gli1 WT + GlaB.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_3-D</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 3-D</infon>
    <infon key="sourcedata_figure_dir">Figure_3-D</infon>
    <passage>
      <offset>0</offset>
      <text>D HEK293T cells were transfected with 12XGliBS&#8208;Luc and pRL&#8208;TK Renilla (normalization control) plus control (empty vector) or Gli1 or Gli1K340A mutant and treated with increasing concentrations of GlaB. Treatment time was 24 h, and control cells were treated with DMSO only. Data show the mean &#177; SD of three independent experiments. *P 0.05 versus DMSO; **P 0.05 K340A versus Gli1 WT.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_4-A</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 4-A</infon>
    <infon key="sourcedata_figure_dir">Figure_4-A</infon>
    <passage>
      <offset>0</offset>
      <text>A qRT-PCR shows Hh target mRNA expression levels determined in 6&#8208;day&#8208;old mouse cerebellar progenitors after s.c. injections of GlaB.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_4-B</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 4-B</infon>
    <infon key="sourcedata_figure_dir">Figure_4-B</infon>
    <passage>
      <offset>0</offset>
      <text>B Representative EGLHE staining of 6&#8208;day&#8208;old mousecerebellum after s.c. injections of GlaB (upper panel); immunohistochemistry shows Gli1 (middle panel) and Ki67 stainings (lower panel). In all images, the scale bar represents 50 &#956;m.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_4-C</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 4-C</infon>
    <infon key="sourcedata_figure_dir">Figure_4-C</infon>
    <passage>
      <offset>0</offset>
      <text>C The graph shows the percentage of EGL thickness reduction in GlaB&#8208;treated mouse cerebella in comparison with vehicle mouse cerebella. Data show the mean &#177; SD of cerebella (n = 10) for each treatment. *P 0.05 versus Ctr.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_4-D</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 4-D</infon>
    <infon key="sourcedata_figure_dir">Figure_4-D</infon>
    <passage>
      <offset>0</offset>
      <text>D BrdU assay in GCPs. Cerebellargranule cell progenitors (GCPs) isolated from 4&#8208;day&#8208;old mice were treated with Shh (recombinant mouseSonic Hedgehog, amino&#8208;terminal peptide, ShhN, 3 &#956;g/ml) and with different concentrations of GlaB, as indicated, for 48 h. Inhibition of cell proliferation was measured as percentage of BrdU incorporation in comparison with DMSO&#8208;treated sample. Shown is the mean of three independent experiments. Error bars indicate SD. *P 0.05 Shh versus DMSO; **P 0.05 Shh + GlaB versus Shh.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_4-E</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 4-E</infon>
    <infon key="sourcedata_figure_dir">Figure_4-E</infon>
    <passage>
      <offset>0</offset>
      <text>E qRT-PCR and show Hh and proliferation target mRNA and protein expression levels determined in ex vivo GCP culture derived from 6&#8208;day&#8208;old mousecerebella after s.c. injections of GlaB. In all qRT-PCR experiments, the results were normalized to endogenous control (&#946;2&#8208;microglobulin and HPRT). *P 0.05 versus Ctr.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_4-F</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 4-F</infon>
    <infon key="sourcedata_figure_dir">Figure_4-F</infon>
    <passage>
      <offset>0</offset>
      <text>F Western blot analysis show Hh and proliferation target mRNA and protein expression levels determined in ex vivo GCP culture derived from 6&#8208;day&#8208;old mousecerebella after s.c. injections of GlaB.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_5-A</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 5-A</infon>
    <infon key="sourcedata_figure_dir">Figure_5-A</infon>
    <passage>
      <offset>0</offset>
      <text>A, B Ex vivo cell cultures from Ptch1+/&#8722;mice MBs were treated with GlaB (5 &#956;M), GANT61 (10 &#956;M) or DMSO only. After the indicated times, a trypan blue count was performed (A) to determine the growth rate of viable cells.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_5-B</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 5-B</infon>
    <infon key="sourcedata_figure_dir">Figure_5-B</infon>
    <passage>
      <offset>0</offset>
      <text>A, B Ex vivo cell cultures from Ptch1+/&#8722;miceMBs were treated with GlaB (5 &#956;M), GANT61 (10 &#956;M) or DMSO only. After the indicated times, Gli1 mRNA expression levels were determined by qRT-PCR (B) normalized to endogenous control (&#946;2&#8208;microglobulin and HPRT).</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_5-C</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 5-C</infon>
    <infon key="sourcedata_figure_dir">Figure_5-C</infon>
    <passage>
      <offset>0</offset>
      <text>C-F GlaB inhibits MB&#8208;SCs' self&#8208;renewal and proliferation. (C) Suspension of single MB&#8208;SCs isolated from Ptch1+/&#8722;mice. MBs were cultured in stem cell medium to allow the formation of primary neurospheres. Primary neurospheres were dissociated and treated with increasing concentrations of GlaB or DMSO only. After 7 days of treatment, the number of secondary neurospheres derived from a known number of single cells was counted. The self&#8208;renewal MB&#8208;SCs' capability is expressed as percentage of neurosphere&#8208;forming cells (left). Representative bright field images of tumor neurospheres after GlaB treatment are also shown (right).</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_5-D</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 5-D</infon>
    <infon key="sourcedata_figure_dir">Figure_5-D</infon>
    <passage>
      <offset>0</offset>
      <text>C-F GlaB inhibits MB&#8208;SCs' self&#8208;renewal and proliferation. (D, E) MB&#8208;SCs isolated from Ptch1+/&#8722;miceMBs were treated for 48 h with GlaB (5 &#956;M) or DMSO only. qRT-PCR analysis show Hh, proliferation and stemness target mRNA expression levels. For qRT-PCR, results were normalized to endogenous control (&#946;2&#8208;microglobulin and HPRT).</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_5-E</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 5-E</infon>
    <infon key="sourcedata_figure_dir">Figure_5-E</infon>
    <passage>
      <offset>0</offset>
      <text>C-F GlaB inhibits MB&#8208;SCs' self&#8208;renewal and proliferation. (D, E) MB&#8208;SCs isolated from Ptch1+/&#8722;miceMBs were treated for 48 h with GlaB (5 &#956;M) or DMSO only. Western blot analysis show Hh, proliferation and stemness target protein expression levels.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_5-F</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 5-F</infon>
    <infon key="sourcedata_figure_dir">Figure_5-F</infon>
    <passage>
      <offset>0</offset>
      <text>C-F GlaB inhibits MB&#8208;SCs' self&#8208;renewal and proliferation. (F) BrdU assay in MB&#8208;SCs treated with GlaB (5 &#956;M) for 24 or 48 h and plated on polylysinated chamber slides. Inhibition of cell proliferation was measured as percentage of BrdU incorporation in comparison with DMSO&#8208;treated sample.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_5-G</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 5-G</infon>
    <infon key="sourcedata_figure_dir">Figure_5-G</infon>
    <passage>
      <offset>0</offset>
      <text>G TUNEL assay in MB&#8208;SCs. MB&#8208;SCs isolated from Ptch1+/&#8722;miceMBs were treated with GlaB (5 &#956;M) and compared to DMSO&#8208;treated sample. Bottom panel shows a Western blot of caspase&#8208;3 in GlaB&#8208;treated versus control cells.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_6-A</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 6-A</infon>
    <infon key="sourcedata_figure_dir">Figure_6-A</infon>
    <passage>
      <offset>0</offset>
      <text>A Change of tumor volume during GlaB or vehicle treatment period (18 days).</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_6-B</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 6-B</infon>
    <infon key="sourcedata_figure_dir">Figure_6-B</infon>
    <passage>
      <offset>0</offset>
      <text>B Representative flank allografts average volumes. Error bars indicate SD. *P 0.05.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_6-C</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 6-C</infon>
    <infon key="sourcedata_figure_dir">Figure_6-C</infon>
    <passage>
      <offset>0</offset>
      <text>C Representative Masson's trichromestaining of tumors; immunohistochemistry of Gli1, Ki67 and TUNEL stainings. Scale bars represent 35 &#956;m for Masson's trichromestaining, 25 &#956;m for Gli1 and TUNEL, and 10 &#956;m for Ki67 stainings.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_6-D</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 6-D</infon>
    <infon key="sourcedata_figure_dir">Figure_6-D</infon>
    <passage>
      <offset>0</offset>
      <text>D Quantification of Ki67 and TUNEL stainings from immunohistochemistry shown in (C). Error bars indicate SD. *P 0.05.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_6-E</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 6-E</infon>
    <infon key="sourcedata_figure_dir">Figure_6-E</infon>
    <passage>
      <offset>0</offset>
      <text>E qRT-PCR analysis show Hh and proliferation target mRNA expression levels. For qRT-PCR, results were normalized to endogenous control (&#946;2&#8208;microglobulin and HPRT). Data show the mean &#177; SD of tumor (n = 6) for each treatment. *P 0.05 versus Ctr.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_6-F</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 6-F</infon>
    <infon key="sourcedata_figure_dir">Figure_6-F</infon>
    <passage>
      <offset>0</offset>
      <text>F Western blot analysis show Hh and proliferation target protein expression levels. Data show the mean &#177; SD of tumor (n = 6) for each treatment. *P 0.05 versus Ctr.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_7-A-B-C</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 7-A-B-C</infon>
    <infon key="sourcedata_figure_dir">Figure_7-A-B-C</infon>
    <passage>
      <offset>0</offset>
      <text>A Representative images (low and high magnification) of HE (upper panel) and Ki67immunohistochemistry staining (lower panel) of a human Daoy MB cell&#8208;derived orthotopic tumor in NOD/SCIDmicecerebella after i.p. injections of GlaB. Scale bars represent 500 or 200 &#956;m for HE staining, and 150 &#956;m or 50 &#956;m for Ki67 staining. B Representative tumor average volumes at the end of treatment. Error bars indicate SD. *P 0.05. C Quantification of Ki67 staining from immunohistochemistry shown in (A). Error bars indicate SD. *P 0.05.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_8-A-B</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 8-A-B</infon>
    <infon key="sourcedata_figure_dir">Figure_8-A-B</infon>
    <passage>
      <offset>0</offset>
      <text>A, B ASZ001 BCC cells were treated with GlaB (5 &#956;M) or DMSO only. After the indicated times, a trypan blue count was performed to determine (A) the growth rate and (B) the percentage of cell death. Data show the mean &#177; SD of three independent experiments. *P 0.05 versus DMSO.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_8-C</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 8-C</infon>
    <infon key="sourcedata_figure_dir">Figure_8-C</infon>
    <passage>
      <offset>0</offset>
      <text>C Gli1 mRNA expression levels were determined by qRT-PCR after treatment of ASZ001 BCC cells with GlaB or DMSO only for the indicated times. Results were normalized to endogenous control (&#946;2&#8208;microglobulin and HPRT). Data show the mean &#177; SD of three independent experiments. *P 0.05 versus DMSO.</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_8-D</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 8-D</infon>
    <infon key="sourcedata_figure_dir">Figure_8-D</infon>
    <passage>
      <offset>0</offset>
      <text>D-H GlaB inhibits Gli1&#8208;dependent BCC tumor growth in ASZ001 BCC allografts in vivo. (D) Change of tumor volume during GlaB or vehicle treatment period (18 days).</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_8-E</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 8-E</infon>
    <infon key="sourcedata_figure_dir">Figure_8-E</infon>
    <passage>
      <offset>0</offset>
      <text>D-H GlaB inhibits Gli1&#8208;dependent BCC tumor growth in ASZ001 BCC allografts in vivo. (E) Representative flank allografts average volumes (upper panel).</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_8-F-G</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 8-F-G</infon>
    <infon key="sourcedata_figure_dir">Figure_8-F-G</infon>
    <passage>
      <offset>0</offset>
      <text>D-H GlaB inhibits Gli1&#8208;dependent BCC tumor growth in ASZ001 BCC allografts in vivo. (F) HE and immunohistochemistry staining of Gli1, Ki67 and TUNEL of allograft tumor samples. Scale bars represent 50 &#956;m for HE, 25 &#956;m for Gli1, 25 &#956;m for Ki67 and 30 &#956;m for TUNEL stainings. (G) Quantification of Ki67 and TUNEL stainings from immunohistochemistry shown in (F)</text>
    </passage>
  </document>
  <document>
    <id>4298015 Figure_8-H</id>
    <infon key="sourcedata_document">1638</infon>
    <infon key="doi">10.15252/embj.201489213</infon>
    <infon key="pmc_id">4298015</infon>
    <infon key="figure">Figure 8-H</infon>
    <infon key="sourcedata_figure_dir">Figure_8-H</infon>
    <passage>
      <offset>0</offset>
      <text>D-H GlaB inhibits Gli1&#8208;dependent BCC tumor growth in ASZ001 BCC allografts in vivo. (H) qRT-PCR of Hh and proliferation target mRNA expression levels. Results were normalized to endogenous control (&#946;2&#8208;microglobulin and HPRT). Shown is the mean &#177; SD of tumor (n = 6) for each treatment. *P 0.05 versus Ctr.</text>
    </passage>
  </document>
</collection>
